Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor

Published:2013-05-31 Issue:4 Volume:36 Page:311-321
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Lim Sang-Woo,Kim Hye-Ran,Kim Hwan-Young,Huh Jung-Wook,Kim Young-Jin,Shin Jong-Hee,Suh Soon-Pal,Ryang Dong-Wook,Kim Hyeong-Rok,Shin Myung-Geun

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13402-013-0136-6.pdf

Reference27 articles.

1. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)

2. E. Half, R. Broaddus, K.D. Danenberg, P.V. Danenberg, G.D. Ayers, F.A. Sinicrope, HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108, 540–548 (2004)

3. J.T. Jorgensen, Targeted HER2 treatment in advanced gastric cancer. Oncology 78, 26–33 (2010)

4. S. Riethdorf, V. Muller, L. Zhang, T. Rau, S. Loibl, M. Komor et al., Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 16, 2634–2645 (2010)

5. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783–792 (2001)

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative parameters of magnetic resonance imaging cannot predict human epidermal growth factor receptor 2 (HER2) status in rectal cancer;Clinical Imaging;2022-03

2. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population;Disease Markers;2020-01-11

3. HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer;Pathology - Research and Practice;2019-05

4. Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole – tissue sections;Polish Journal of Pathology;2018

5. Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer;Medicine;2015-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3